Market Intelligence, Clinical Progress, and High-Purity Reagents for Isoform-Selective Inhibitor Screening, Nuclear Translocation Studies, and T-Cell Activation Assays in Immuno-Oncology and Autoimmune Indications.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DGKZ drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | DGKZ Full-Length & Catalytic Domain Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. Theoretical MW confirmed. |
View DGKZ Products |
| Gene Delivery | DGKZ Promise-ORF / Lentivirus Full-length ORF for stable cell lines. CMV promoter. Puromycin selection. |
View DGKZ Products |
| Benchmark Ab | Anti-DGKZ Recombinant Rabbit mAb Sequence-verified clone for Western blot, ICC/IF validation. |
View DGKZ Products |
| Validator | DGKZ siRNA Set (3 target-specific + 1 control) For knockdown verification in cell-based signaling assays. |
View DGKZ Products |
| Counter-Screen A | DGKA (Diacylglycerol Kinase Alpha) Recombinant Protein Critical isoform for selectivity screening (Type I DGK). |
View DGKA Products |
| Counter-Screen B | DGKD (Diacylglycerol Kinase Delta) Recombinant Protein Type II DGK homolog for cross-reactivity evaluation. |
View DGKD Products |
| Pathway Partner | RASGRP1 Recombinant Protein Downstream DAG sensor, alternative immune checkpoint target. |
View RASGRP1 Products |
| Related Target | PRKCA (PKC-alpha) & PRKCD (PKC Delta) Downstream DAG effectors for pathway synergy and functional validation. |
View PRKCA Products / View PRKCD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Isoform Selectivity (DGKZ vs DGKA/DGKD) | Purified DGK Family Panel proteins with verified identities by Mass Spec, >95% purity, distinct tag systems for multiplexing. |
| Nuclear Translocation Detection | Anti-DGKZ Antibody optimized for IF/ICC; Lentivirus particles for stable expression in Jurkat T-cells. |
| Enzymatic Activity Screening | Full-length DGKZ with native folding (Theoretical MW verified); suitable for lipid kinase assays. |
| T Cell Functional Assays | Endotoxin-Controlled (<1 EU/µg) proteins suitable for primary lymphocyte culture. |
| Biochemical Assay Window & Specificity | High-purity WT and Kinase-Dead mutant proteins available as positive/negative controls. |
| Cross-species Translation | Human, Mouse, and Cynomolgus DGKZ recombinant proteins with theoretical MW alignment. |
| False Positives from Non-specific Binding | DGKZ-specific siRNA included for target engagement confirmation in cell lysates. |
Live DGKZ R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DGKZ (Diacylglycerol Kinase Zeta) therapeutics is intensifying, with major players focusing on small molecule inhibitors for immuno-oncology. DGKZ acts as a critical negative regulator of T-cell activation by consuming diacylglycerol (DAG). As first-generation immunotherapies reach maturity, the next wave of R&D is targeting intracellular checkpoints like DGKZ to restore exhausted T-cells and enhance the efficacy of PD-1/PD-L1 blockades in refractory solid tumors. Additionally, isoform-selective inhibitors and CNS-penetrant compounds are being explored for autoimmune indications such as multiple sclerosis. The pipeline includes small molecules, allosteric modulators, PROTACs, and combination strategies with CAR-T and checkpoint inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Large Pharma, Oncology Biotechs | Solid Tumors (Immuno-Oncology), Autoimmune | Isoform Selectivity Panel (DGKA/DGKZ/DGKD) – Need high-purity homologs |
| Allosteric Modulator | CNS-Focused Discovery Programs | Multiple Sclerosis, Schizophrenia | Conformation-Specific Binding Assays (need full-length WT protein) |
| Targeted Protein Degradation (PROTAC) | Platform Technology Companies | Immuno-Oncology, Hematologic Malignancies | Binary/Ternary Complex Formation (need purified DGKZ + ligands) |
| siRNA / ASO | Preclinical Innovators | Autoimmune, Oncology | Target Knockdown (Need Validated siRNA sets) |
| Cell Therapy (CAR-T) | Academic Consortia | Refractory Cancers | Cell Engineering (Need Lentivirus for Stable Knockout/Overexpression) |
| Combination (IO) | Pharma Consortiums | Immuno-Oncology | Isoform Selectivity Panel (need DGKZ vs DGKA proteins) |